BB's Stock Haven

[Edward]

Informational- Article out today.


Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results


Apr. 26, 2021 3:32 PM ET Citius Pharmaceuticals, Inc. (CTXR)By: Jonathan M Block, SA News Editor1 Comment

Shares of Citius Pharmaceuticals (NASDAQ:CTXR) are up more than 5% in afternoon trading (closed up 6.74%) amid anticipation that the company will soon release positive phase 3 data for its lead product candidate Mino-Lok.

The product is an antibiotic lock solution to treat patients with central venous catheter-related bloodstream infections.

These infections can be especially serious in cancer patients receiving treatment through the catheter.

In February, Seeking Alpha contributor North Shore Research wrote that Mino-Lok will have no competition and will reduce the need to remove and replace the catheter, which can sometimes lead to complications.

North Shore Research has an $8 price target on shares.